You are here
Unmet Needs and Rationale for Combination Therapies for Diabetes Specialists
for Diabetes Specialists
In this course, you will learn about the rationale for adding a glucagon-like peptide-1 (GLP-1) receptor agonist to basal insulin therapy. The complementary effects of basal insulin–GLP-1 receptor agonist combination therapy will be discussed in terms of glycaemic control, change in body weight, and risk of hypoglycaemia.
In this webcast, Professor Colagiuri discusses clinical inertia and the drawbacks of insulin. He also discusses the advantages of combining insulin with a GLP-1 RA when intensifying treatment in patients with type 2 diabetes.
Efficacy and safety of LixiLan, a titratable fixed-ratio combination of lixisenatide and insulin glargine, versus insulin glargine in type 2 diabetes inadequately controlled on metformin monotherapy: the LixiLan proof-of-concept randomized trial
On this page, you can access an article and summary slides belonging to a series of three recent publications specially curated for this course by Professor Fonseca. These articles cover the rationale behind combining insulin and GLP-1 RA, the effects of this combination using continuous glucose monitoring, and the outcomes of 2 important clinical trials with the new fixed-ratio basal insulin–GLP-1 RA combination therapy.